Notice of Results

14 September 2018

AIM: AMYTESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

NOTICE OF RESULTS

Amryt, a biopharmaceutical company focused on rare and orphan diseases, will announce interim results, covering the six months to 30 June 2018, on Wednesday, 26 September 2018.

Management will host a conference call for analysts and investors at 8.30am BST on 26 September 2018. To register your interest for the call, please email ir@amrytpharma.com.

- Ends -

Enquiries:

About Amryt

Amryt is a biopharmaceutical company focused on acquiring, developing & commercialising products that help improve the lives of patients where there is a high unmet medical need.

Lojuxta, Amryt's lead commercial asset, is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature narrowing and blocking of blood vessels, heart attacks and strokes, even at a very young age if not properly diagnosed or receiving adequate treatment. Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.

Amryt holds an exclusive licence to sell Lojuxta (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.

Amryt's lead development asset, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no treatment. It is currently in Phase III clinical trials. The European and US market opportunity for EB is estimated to be in excess of €1 billion.

Amryt's earlier stage product, AP102, is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including Acromegaly and Cushing's disease. 

In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.

For more information on Amryt, please visit amrytpharma.com